Novartis Adopts Boomi iPaaS to Reduce Development Time and Lower TCO
Industry & Market
$49.89B USD (2020)
NetSuite, 3PL partner
Novartis Adopts the Boomi AtomSphere Platform to Reduce Development Time and Lower TCO
Novartis International AG
Seeking an alternative to expensive, inflexible on-premises middleware solutions, Novartis wanted to achieve greater agility while lowering costs. The company needed an integration approach that it could easily extend to accommodate cloud and mobile use cases.
Integration is rarely a core competency of IT, which means it is often outsourced — leading to costs that are difficult to sustain. Novartis had several goals in its search for an in-house integration solution, including:
- Reduce development time to achieve desired business results
- Increase deployment flexibility, scalability and performance
- Centralize control over distributed integration processes to alleviate data security and privacy concerns
Prior to deployment of Boomi, Novartis used two on-premises middleware products. The cost per integration interface varied from $30,000 to $50,000. Even small changes took extensive effort, which limited the number of feasible projects.
Hardware and software upgrades to support the on-premises middleware were also expensive and time consuming. And, for some projects, the on-premises solutions posed compliance risks.
Finally, neither product could support the company’s interest in using cloud services for a range of application-to-application, B2B and mobile integration scenarios.
How Boomi Helped
Boomi helped Novartis shift to an integration approach that delivered faster business results, while ensuring scalability, performance and lower cost.
Boomi completed its proof-of-concept pilot in only 25 hours, far ahead of competing vendors. The PoC required updating Salesforce user profiles with internal Novartis data and retiring accounts. The process involved modifying endpoint interfaces to meet the data mapping needs of Novartis.
Novartis estimated that Boomi delivered cost savings of $18,250, reducing costs by 73 percent when compared to its on-premises middleware solutions.
Novartis began its migration to Boomi in two phases. In phase one, Boomi:
- Delivered overall savings of 30 percent
- Reduced required server capacity by 50 percent
- Cut development time for new interfaces to two to three weeks
- Deployed twice the number of interfaces and processes in a sixth of the time previously needed.
Novartis expects phase two savings of 30–35 percent. In addition, the company plans to use Boomi to expose clinical data via APIs for consumption by mobile applications.
Over the long term, Novartis expects Boomi to deliver TCO savings of 50 percent.